Vir Biotechnology (VIR) Common Equity (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Common Equity data on file, last reported at $812.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 22.14% year-over-year to $812.8 million; the trailing twelve-month figure through Mar 2026 stood at $812.8 million (down 22.14% YoY), and the FY2025 full-year result was $765.3 million, down 33.48% from the prior year.
• Common Equity grew to $812.8 million in Q1 2026, from $765.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.1 billion in Q3 2022 to a low of $765.3 million in Q4 2025.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 207.4% in 2022 and sank 35.84% in 2025, its largest moves.
• Tracing VIR's Common Equity over 5 years: stood at $2.1 billion in 2022, then retreated by 23.47% to $1.6 billion in 2023, then fell by 27.66% to $1.2 billion in 2024, then sank by 33.48% to $765.3 million in 2025, then rose by 6.21% to $812.8 million in 2026.
• Business Quant data shows VIR's Common Equity at $812.8 million in Q1 2026, $765.3 million in Q4 2025, and $796.1 million in Q3 2025.